<DOC>
	<DOC>NCT00309530</DOC>
	<brief_summary>This clinical investigation examined the effectivity 5-fluorouracil, of adding levamisol or interferon to 5-fluorouracil, and of a 5-fluorouracil/levamisol/interferon triple combination, in terms of recurrence-free and overall survival in curatively operable colon carcinoma Stage III.</brief_summary>
	<brief_title>Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C</brief_title>
	<detailed_description />
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Patients with histologically verified, curatively operated colon carcinoma Stage III (R0, T14, N13, M0) Age: less than 80 years WHO Performace Status &gt; 2 Adequate bone marrow reserve Informed consent Rectal cancer R1, R2, carcinosis peritonei Start of chemo or chemoimmunotherapy &gt; 42 days postop; other adjuvant radiotherapy, chemotherapy or immunotherapy Serious concomitant disease, in particular chronically inflammatory large intestine, cardiopathic disease, malignant second carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 1999</verification_date>
	<keyword>Fluorouracil</keyword>
	<keyword>Levamisol</keyword>
	<keyword>Interferon</keyword>
	<keyword>Colon cancer</keyword>
</DOC>